GLOPERBA Drug Patent Profile
✉ Email this page to a colleague
When do Gloperba patents expire, and what generic alternatives are available?
Gloperba is a drug marketed by Scilex Pharms and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has three patent family members in two countries.
The generic ingredient in GLOPERBA is colchicine. There are sixteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the colchicine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gloperba
A generic version of GLOPERBA was approved as colchicine by AMNEAL PHARMS on September 28th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GLOPERBA?
- What are the global sales for GLOPERBA?
- What is Average Wholesale Price for GLOPERBA?
Summary for GLOPERBA
| International Patents: | 3 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 113 |
| Clinical Trials: | 1 |
| Patent Applications: | 5,036 |
| Drug Prices: | Drug price information for GLOPERBA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GLOPERBA |
| What excipients (inactive ingredients) are in GLOPERBA? | GLOPERBA excipients list |
| DailyMed Link: | GLOPERBA at DailyMed |
Recent Clinical Trials for GLOPERBA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Helwan University | Phase 3 |
Pharmacology for GLOPERBA
| Drug Class | Alkaloid |
Paragraph IV (Patent) Challenges for GLOPERBA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| GLOPERBA | Oral Solution | colchicine | 0.6 mg/5 mL | 210942 | 1 | 2020-04-02 |
US Patents and Regulatory Information for GLOPERBA
GLOPERBA is protected by six US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | 12,274,751 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | 10,383,821 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | 12,514,819 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | 10,383,820 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | 10,226,423 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Scilex Pharms | GLOPERBA | colchicine | SOLUTION;ORAL | 210942-001 | Jan 30, 2019 | RX | Yes | Yes | 9,907,751 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for GLOPERBA
See the table below for patents covering GLOPERBA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2019126579 | ⤷ Start Trial | |
| European Patent Office | 3426227 | COMPOSITION ET MÉTHODE D'UTILISATION DE LIQUIDE ORAL DE COLCHICINE (COMPOSITION AND METHOD OF USE OF COLCHICINE ORAL LIQUID) | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017156392 | ⤷ Start Trial | |
| European Patent Office | 3426227 | COMPOSITION ET MÉTHODE D'UTILISATION DE LIQUIDE ORAL DE COLCHICINE (COMPOSITION AND METHOD OF USE OF COLCHICINE ORAL LIQUID) | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017156392 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
DrugChatter Q&A for GLOPERBA
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch